http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories View More Recent Stories
-
BeiGene (BGNE) Announces Acceptance of 11th Regulatory Submission for PD-1 Inhibitor Tislelizumab in China
-
BeiGene Announces Acceptance of 11th Regulatory Submission for PD-1 Inhibitor Tislelizumab in China
-
BeiGene Announces Strategic Alliance with Ontada to Improve U.S. Community Oncology Care
-
BeiGene (BGNE) Reports Positive Global Phase 3 Trial Results for Tislelizumab
-
BeiGene Announces Positive Global Phase 3 Trial Results for PD-1 Inhibitor Tislelizumab in First-Line Unresectable Hepatocellular Cancer
-
BeiGene Reports Second Quarter 2022 Financial Results
-
BeiGene (BGNE) Announces FDA Deferred Action on BLA for PD-1 Inhibitor Tislelizumab in 2L ESCC
-
BeiGene Provides Regulatory Update on the U.S. Biologics License Application (BLA) for PD-1 Inhibitor Tislelizumab in 2L ESCC
-
BeiGene Appoints Chan Lee as General Counsel
-
BeiGene (BGNE) Collaborates with InnoRNA to Jointly Discover Novel mRNA Therapies
-
BeiGene Announces Strategic Research Collaboration with InnoRNA to Jointly Discover Novel mRNA Therapies
-
BeiGene (BGNE) Reports Data Showing Overall Survival Benefit for Tislelizumab Plus Chemotherapy in First-Line Advanced or Metastatic Esophageal Squamous Cell Carcinoma
-
BeiGene Announces Late-Breaking Data at ESMO GI Showing Overall Survival Benefit for Tislelizumab Plus Chemotherapy in First-Line Advanced or Metastatic Esophageal Squamous Cell Carcinoma
-
BeiGene Announces Acceptance of Supplemental Biologics License Application in China for Anti-PD-1 Inhibitor Tislelizumab
-
BeiGene (BGNE) Announces BRUKINSA Is Approved in 50 Markets
-
BeiGene Announces BRUKINSA™ (zanubrutinib) Is Approved in 50 Markets
-
BeiGene (BGNE) Announces PDUFA Extension for sNDA for BRUKINSA for the Treatment of CLL/SL
-
BeiGene Announces PDUFA Goal Date Extension for U.S. sNDA for BRUKINSA for the Treatment of CLL/SLL
-
BeiGene (BGNE) Announces China NMPA's Approval of Tislelizumab for Recurrent or Metastatic Nasopharyngeal Cancer
-
BeiGene (BGNE) Highlights Growing Portfolio and Pipeline Targeting Hematologic Malignancies at EHA
-
China NMPA Approves Tislelizumab for Recurrent or Metastatic Nasopharyngeal Cancer
-
BeiGene Highlights Growing Portfolio and Pipeline Targeting Hematologic Malignancies at European Hematology Association 2022 Congress
-
BeiGene to Present at the Goldman Sachs 43rd Annual Global Healthcare Conference
-
BeiGene Clinical Data Presentations at 2022 ASCO Annual Meeting Demonstrate Mature and Growing Oncology Portfolio
-
BeiGene Strengthens European Presence With the Opening of Regional Office in Basel, Switzerland
-
BeiGene to Demonstrate Strength of Hematology Portfolio and Pipeline at European Hematology Association 2022 Congress
-
BeiGene Reports First Quarter 2022 Financial Results
-
BeiGene (BGNE) Announces the Approval in China of BLINCYTO
-
BeiGene Announces the Approval in China of BLINCYTO® (Blinatumomab) for Injection for Pediatric Patients with Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia (ALL)
-
BeiGene Breaks Ground on New Manufacturing and Clinical R&D Center at the Princeton West Innovation Campus in New Jersey
-
BeiGene (BGNE) Reports BRUKINSA Approved in Uruguay in Mantle Cell Lymphoma, Marginal Zone Lymphoma, and Waldenstrom’s Macroglobulinemia
-
BeiGene Announces BRUKINSA (zanubrutinib) Approval in Uruguay in Mantle Cell Lymphoma, Marginal Zone Lymphoma, and Waldenström’s Macroglobulinemia
-
BeiGene to Present Clinical Data from Innovative Oncology Portfolio at 2022 ASCO Annual Meeting
-
BeiGene (BGNE) Reports Phase 3 Trial of Tislelizumab in Combination with Chemotherapy Meets Primary Endpoint in First-Line Advanced Esophageal Squamous Cell Carcinoma
-
Global Phase 3 Trial of BeiGene’s PD-1 Inhibitor, Tislelizumab, in Combination with Chemotherapy Meets Primary Endpoint in First-Line Advanced Esophageal Squamous Cell Carcinoma
-
BeiGene Introduces Global Environmental, Social, and Governance Strategy
-
Biocytogen Signs RenMab™/RenLite™ Licensing Agreement with BeiGene
-
BeiGene Provides Grant to Crossroads4Hope to Fund Psychosocial Support Programs for Cancer Patients and Communities in New Jersey
-
BeiGene (BGNE) Reports Updated Results from Phase 3 RATIONALE-309 Trial of PD-1 Inhibitor Tislelizumab in First-Line RM-NPC
-
BeiGene Presents Updated Results from Phase 3 RATIONALE-309 Trial of PD-1 Inhibitor Tislelizumab in First-Line RM-NPC in Virtual ASCO Plenary Series
-
BeiGene (BGNE) Announces China NMPA Approves Tislelizumab for Patients with Second-Line Esophageal Squamous Cell Carcinoma
-
China NMPA Approves Tislelizumab for Patients with Second-Line Esophageal Squamous Cell Carcinoma
-
BeiGene (BGNE) Announces IRC Determined BRUKINSA Demonstrated Superior Overall Response Rate Versus Ibrutinib in Final Response Analysis of ALPINE Trial in Chronic Lymphocytic Leukemia
-
IRC Determines BRUKINSA® (Zanubrutinib) Demonstrates Superior Overall Response Rate Versus Ibrutinib in Final Response Analysis of ALPINE Trial in Chronic Lymphocytic Leukemia
-
BeiGene to Present Clinical Results and Biomarker Data on Tislelizumab in Solid Tumors at the AACR Annual Meeting 2022
-
BeiGene (BGNE) Announces European Acceptance of MAA for Tislelizumab for the Treatment of Patients with ESCC and NSCLC
-
BeiGene Announces European Medicines Agency Acceptance of Marketing Authorization Applications for Tislelizumab for the Treatment of Patients with ESCC and NSCLC
-
BeiGene and Medison Announce Approval and National Reimbursement in Israel for BRUKINSA® (zanubrutinib) for the Treatment of Waldenström's Macroglobulinemia
-
BeiGene (BGNE) Announces China NMPA Approves Tislelizumab for Patients with Microsatellite Instability-High or Mismatch Repair-Deficient Solid Tumors
-
China NMPA Approves Tislelizumab for Patients with Microsatellite Instability-High or Mismatch Repair-Deficient Solid Tumors
